Neumora Therapeutics, Inc.

44 Days Left

Offering Date:
common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023.

Lead Plaintiff Deadline:
April 07, 2025

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Allegations

The filed complaint alleges that Neumora Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn’s original Phase Two trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder, MDD, to show that Navacaprant, Neumora’s flagship therapeutic candidate, offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Neumora Therapeutics, Inc. purchased or acquired during the class period listed above and/or pursuant to the stock offering(s) referenced above.

Lead Plaintiff Deadline

If you suffered a loss in Neumora Therapeutics, Inc. during the relevant time frame or pursuant to the relevant offering(s), you have until April 07, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.